Artiva Biotherapeutics In... (ARTV)
Company Description
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate.
The company was incorporated in 2019 and is headquartered in San Diego, California.
| Country | United States |
| IPO Date | n/a |
| Industry | n/a |
| Sector | n/a |
| Employees | 89 |
| CEO | Dr. Peter Flynn Ph.D. |
Contact Details
Address: 5505 Morehouse Drive San Diego, California United States | |
| Website | https://www.artivabio.com |
Stock Details
| Ticker Symbol | ARTV |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | n/a |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Jennifer Kinsbruner Bush Esq., J.D. | Executive Vice President, Chief Operating Officer, Chief Legal Officer, Corporate Secretary & Compliance Officer |
| Benjamin Dewees | Senior Vice President of Regulatory Affairs |
| Dr. David Moriarty Ph.D. | Senior Vice President of Clinical Operations |
| Dr. Peter Flynn Ph.D. | Co-Founder & Strategic Advisor |
| Feng Xu | Senior Vice President of Biometrics |